Natural Capsules Ltd

BSE: 524654

23

total announcements

NATCAPSUQ.BO · 15 min delayed

Key Stats · Yahoo Finance · as of 31 Oct 2026

Market Cap

₹142 Cr

P/E (Forward)

11.1

EPS (TTM)

₹-24.01

52W Low

₹134.00

52W High

₹237.00

Dividend Yield

0.00%

Beta

0.01

Price / Book

0.6

Debt / Equity

49.2

Revenue (TTM)

₹191 Cr

Gross Margin

42.96%

Operating Margin

-6.59%

BSECompany Update9 Oct 2026

Natural Capsules Ltd

Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the certificate received from Cameo Corporate Services Limited, Registrar & Share Transfer Agent ("RTA") for the quarter ended September 30, 2026.

Natural Capsules Ltd has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing of new securities on the stock exchanges.

Read more →📎 1 attachment
BSEInsider Trading / SASTinsider_trading25 Sept 2026

Natural Capsules Ltd

We wish to inform that the "Trading Window" for dealing in the equity shares of the company shall remain closed for all Designated Person and their immediate relatives with effect from October 01, 2026 till the conclusion of 48 hours after the declaration of Financial Results of the Company for the Quarter ended September 30, 2026.

Natural Capsules Ltd announces closure of trading window for all Designated Persons and their immediate relatives from October 1, 2026, till 48 hours after the declaration of financial results for the quarter ended September 30, 2026.

Read more →📎 1 attachment
BSECompany UpdateFundraise2 Sept 2026

Natural Capsules Ltd

We wish to inform you that the company has today, Wednesday, September 02, 2026, completed the dispatch of the Corrigendum to the EGM Notice to all eligible members of the Company.

Natural Capsules Ltd has dispatched a Corrigendum to the EGM Notice to all eligible members, incorporating changes in the issue price and quantity of Equity Shares and Convertible Warrants proposed to be issued on a preferential basis.

Read more →📎 1 attachment
BSEBoard MeetingFundraise1 Sept 2026

Natural Capsules Ltd

Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....

Natural Capsules Ltd has informed BSE that a Board Meeting is scheduled on 02/09/2026 to consider and approve the valuation report, revise the issue/allotment price and quantity, and approve the revised notice & schedule for the proposed preferential issue of equity shares/securities.

Read more →📎 1 attachment
BSEAGM/EGMFundraise18 Aug 2026

Natural Capsules Ltd

We are hereby submitting the Notice of the Extraordinary General Meeting (EGM) of the Company scheduled to be held on Wednesday, September 09, 2026 at 12:00 PM (IST) through Video Conference ....

Natural Capsules Ltd has announced a Notice of Extraordinary General Meeting (EGM) to be held on September 09, 2026, to consider a preferential issue of 1,25,000 equity shares at Rs. 160/- per share, aggregating to Rs. 2,00,00,000.

Read more →📎 1 attachment
BSECompany UpdateResults14 Aug 2026

Natural Capsules Ltd

We hereby inform that the Unaudited Financial Results for the Quarter ended June 30, 2026, has been published in Business Line, an English Daily & Sanjevani a Kannada daily.

Natural Capsules Ltd published unaudited financial results for Q1 2026, with revenue and profit before tax increasing 16% and 7% year-over-year, respectively. The company's Africa business grew 44% and 21% in revenue and profit, respectively. Gokaldas Exports, a related party, secured India's largest single-cluster Al infrastructure for the US-based cloud innovator Together AL.

Read more →📎 1 attachment
BSECompany UpdateResults13 Aug 2026

Natural Capsules Ltd

Please find enclosed herewith the copy of Investors Presentation in connection with the Unaudited Consolidated & Standalone Financial Results for quarter ended June 30, 2026.

Natural Capsules Ltd has released its Q1FY27 financial results, showing revenue of ₹48.71 Cr, EBITDA of ₹1.12 Cr, and PAT of ₹-5.74 Cr. The company witnessed sustained demand across its capsule products and improved realisations, but faced challenges in the HPMC segment due to US market uncertainty and geopolitical issues in the APl business.

Read more →📎 1 attachment
BSECompany UpdateResults13 Aug 2026

Natural Capsules Ltd

Please find enclosed herewith the copy of Press Release made to analysts and investors in connection with the Unaudited Consolidated & Standalone Financial Results for quarter ended June 30, 2026.

Natural Capsules Ltd reported its Q1FY27 results, with revenue of ₹4871 Cr, EBITDA of ₹1.12 Cr, and EBITDA margins of 2.30%. The company witnessed sustained demand across its capsule products and improved realisations, but faced challenges in the HPMC segment due to uncertainty in the US market. The API business presented a mixed picture, with ongoing geopolitical uncertainty and headwinds from the depreciation of the Indian rupee.

Read more →📎 1 attachment
BSEAGM/EGMResults12 Aug 2026

Natural Capsules Ltd

33rd Annual General Meeting of the Company held on Wednesday August 12, 2026 at 12.10 P.M. through Video conferencing ("VC") other Audio-visual Means ("OAVM") and was concluded at 01:00 PM.

Natural Capsules Ltd held its 33rd Annual General Meeting on August 12, 2026, where the company's audited consolidated and standalone financial statements for the year ended March 31, 2026, were adopted, and several resolutions were passed, including the reappointment of directors, revision of remuneration, and approval of related party transactions.

Read more →📎 1 attachment
BSEBoard MeetingFundraise9 Aug 2026

Natural Capsules Ltd

Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Update on board meeting 1. ....

Natural Capsules Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve the unaudited consolidated & standalone financial results for the quarter ended June 30, 2026, and also to evaluate a proposal for raising funds by way of issue of equity shares, convertibles, and/or any other eligible securities on a preferential basis.

Read more →📎 1 attachment
Page 1 of 2Next →